Scott Greenwald

Dr. Scott Greenwald is a research fellow in the Department of Ophthalmology at Harvard Medical School and a member of the Ocular Genomics Institute at the Massachusetts Eye and Ear Infirmary. He is currently developing a gene therapy for treating the NMNAT1 form of Leber Congenital Amaurosis, an inherited disease that causes irreversible blindness in young children, and investigating the cellular mechanisms underlying this condition. Scott graduated from the University of Pennsylvania with a degree in the biological basis of behavior before joining Second Sight Medical Products to research the perceptual effects of artificial retinal stimulation in patients with advanced retinitis pigmentosa. He then went on to study cone photoreceptor dysfunction associated with inherited retinal diseases at the University of Washington where he earned a PhD in neurobiology.